OpGen (NASDAQ:OPGN) Coverage Initiated at StockNews.com

Analysts at StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN) in a report released on Monday. The firm set a “sell” rating on the medical research company’s stock.

OpGen Price Performance

OpGen stock opened at $1.98 on Monday. OpGen has a fifty-two week low of $1.75 and a fifty-two week high of $38.40. The stock has a fifty day moving average of $2.20 and a two-hundred day moving average of $3.52.

OpGen (NASDAQ:OPGN) last posted its quarterly earnings data on Monday, August 19th. The medical research company reported ($1.18) EPS for the quarter. The company had revenue of $0.03 million for the quarter. OpGen had a negative return on equity of 1,827.76% and a negative net margin of 1,140.36%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in OpGen stock. Chase Investment Counsel Corp bought a new stake in OpGen, Inc. (NASDAQ:OPGN) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned 2.63% of OpGen as of its most recent filing with the Securities & Exchange Commission. 2.68% of the stock is currently owned by institutional investors.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.